FDA Panel to Discuss Johnson & Johnson and Legend Biotech’s CAR-T Therapy for Multiple Myeloma Risk-Benefit Assessment
Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee is set to convene on Friday, March 15th, to deliberate on Johnson & Johnson’s supplemental biologics license application for Carvykti, developed by Legend Biotech Corporation, to treat relapsed or refractory multiple myeloma patients. The focus of the meeting will be on evaluating the results of the CARTITUDE-4 study and determining if the benefits of Carvykti outweigh the risks for the proposed indication. Of particular concern …